Court denies injunction blocking Surmodics acquisition by GTCR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
- Anthropic logged net loss of over $80 billion in first half of 2026
- Xpeng shares climb as licensing model gains focus
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
November 10, 2025 7:00 PM ESTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX) (Surmodics or the Company), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the District Court) has denied a request by the U.S. Federal Trade Commission (the FTC) and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR LLC (GTCR) from consummating the proposed acquisition of the Company by an affiliate of GTCR (the Merger).
Consummation of the... More



